Literature DB >> 16456664

Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis.

Yan Zhang1, Hiroaki Matsuo, Eishin Morita.   

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by severe itching, erythema and edema resistant to anti-histamine therapy. Vascular endothelial growth factor (VEGF) is a potent agent that causes hyperpermeability of blood vessels and endothelial cell proliferation, and might be involved in the persisting erythema and edema in AD. In this study, we used extraction of stratum corneum with physiological saline to detect VEGF produced in the lesions of AD. Biological activity of VEGF was assayed by proliferation of cultured human umbilical vein endothelial cells in vitro. As a result, we found that the amount of VEGF produced in lesional scales was approximately 25 times higher than that in normal stratum corneum. Moreover, VEGF 121 isoform that exclusively induces hyperpermeability of blood vessels was a predominant component in the lesional scales suggesting that this factor plays an important role in the persisting erythema and edema in the AD lesions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16456664     DOI: 10.1007/s00403-006-0641-9

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  20 in total

1.  Angiogenesis in the skin of SHARPIN-deficient mice with chronic proliferative dermatitis.

Authors:  Harm HogenEsch; Mario Sola; Timothy M Stearns; Kathleen A Silva; Victoria E Kennedy; John P Sundberg
Journal:  Exp Mol Pathol       Date:  2016-10-26       Impact factor: 3.362

2.  Topical treatment of contact dermatitis by pine processionary caterpillar.

Authors:  Pedro Cuevas; Javier Angulo; Guillermo Giménez-Gallego
Journal:  BMJ Case Rep       Date:  2011-08-11

3.  Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor.

Authors:  Cornelia Halin; Hermann Fahrngruber; Josef G Meingassner; Guido Bold; Amanda Littlewood-Evans; Anton Stuetz; Michael Detmar
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

4.  In vivo and in vitro analysis of low level light therapy: a useful therapeutic approach for sensitive skin.

Authors:  M Choi; J E Kim; K H Cho; J H Lee
Journal:  Lasers Med Sci       Date:  2013-02-10       Impact factor: 3.161

5.  Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis.

Authors:  L Ma; H-B Xue; X-H Guan; C-M Shu; J-H Zhang; J Yu
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

6.  Sub-clinical assessment of atopic dermatitis severity using angiographic optical coherence tomography.

Authors:  Robert A Byers; Raman Maiti; Simon G Danby; Elaine J Pang; Bethany Mitchell; Matt J Carré; Roger Lewis; Michael J Cork; Stephen J Matcher
Journal:  Biomed Opt Express       Date:  2018-03-29       Impact factor: 3.732

7.  An important role of blood and lymphatic vessels in inflammation and allergy.

Authors:  Silvana Zgraggen; Alexandra M Ochsenbein; Michael Detmar
Journal:  J Allergy (Cairo)       Date:  2013-01-31

8.  VEGF is involved in the increase of dermal microvascular permeability induced by tryptase.

Authors:  Qianming Bai; Xiaobo Li; Xinhong Wang; Yali Xu; Li Wang; Qingyong Zhang; Lianhua Yin
Journal:  ISRN Dermatol       Date:  2012-05-15

9.  IL-9 induces VEGF secretion from human mast cells and IL-9/IL-9 receptor genes are overexpressed in atopic dermatitis.

Authors:  Nikolaos Sismanopoulos; Danae A Delivanis; Konstantinos D Alysandratos; Asimenia Angelidou; Magdalini Vasiadi; Anastasia Therianou; Theoharis C Theoharides
Journal:  PLoS One       Date:  2012-03-08       Impact factor: 3.240

10.  Increased plasma concentration of vascular endothelial growth factor in patients with atopic dermatitis and its relation to disease severity and platelet activation.

Authors:  E Koczy-Baron; J Jochem; A Kasperska-Zajac
Journal:  Inflamm Res       Date:  2012-08-23       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.